Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 5
2007 2
2008 2
2010 1
2011 1
2012 2
2013 1
2014 4
2015 3
2016 1
2017 2
2018 4
2019 2
2021 1
2022 1
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA; Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Español de Médula Ósea; German High-Grade Lymphoma Study Group; German Hodgkin's Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute. Cheson BD, et al. J Clin Oncol. 2014 Sep 20;32(27):3059-68. doi: 10.1200/JCO.2013.54.8800. J Clin Oncol. 2014. PMID: 25113753 Free PMC article.
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).
Iland HJ, Bradstock K, Supple SG, Catalano A, Collins M, Hertzberg M, Browett P, Grigg A, Firkin F, Hugman A, Reynolds J, Di Iulio J, Tiley C, Taylor K, Filshie R, Seldon M, Taper J, Szer J, Moore J, Bashford J, Seymour JF; Australasian Leukaemia and Lymphoma Group. Iland HJ, et al. Blood. 2012 Aug 23;120(8):1570-80; quiz 1752. doi: 10.1182/blood-2012-02-410746. Epub 2012 Jun 19. Blood. 2012. PMID: 22715121 Free article. Clinical Trial.
The treatment of acute promyelocytic leukemia has improved considerably after recognition of the effectiveness of all-trans-retinoic acid (ATRA), anthracycline-based chemotherapy, and arsenic trioxide (ATO). ...
The treatment of acute promyelocytic leukemia has improved considerably after recognition of the effectiveness of all-trans-retinoic …
How comparable are patient outcomes in the "real-world" with populations studied in pivotal AML trials?
Tiong IS, Wall M, Bajel A, Kalro A, Fleming S, Roberts AW, Thiagarajah N, Chua CC, Latimer M, Yeung D, Marlton P, Johnston A, Enjeti A, Fong CY, Cull G, Larsen S, Kennedy G, Schwarer A, Kipp D, Ramanathan S, Verner E, Tiley C, Morris E, Hahn U, Moore J, Taper J, Purtill D, Warburton P, Stevenson W, Murphy N, Tan P, Beligaswatte A, Mutsando H, Hertzberg M, Shortt J, Szabo F, Dunne K, Wei AH; Australasian Leukaemia and Lymphoma Group (ALLG). Tiong IS, et al. Blood Cancer J. 2024 Mar 26;14(1):54. doi: 10.1038/s41408-024-00996-x. Blood Cancer J. 2024. PMID: 38531863 Free PMC article.
Governmental cancer data often lacks details on treatment, response, and molecular characterization of disease sub-groups. The Australasian Leukaemia and Lymphoma Group National Blood Cancer Registry (ALLG NBCR) includes source information on morphology, cytogenetic …
Governmental cancer data often lacks details on treatment, response, and molecular characterization of disease sub-groups. The Australasi …
Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.
Iland HJ, Collins M, Bradstock K, Supple SG, Catalano A, Hertzberg M, Browett P, Grigg A, Firkin F, Campbell LJ, Hugman A, Reynolds J, Di Iulio J, Tiley C, Taylor K, Filshie R, Seldon M, Taper J, Szer J, Moore J, Bashford J, Seymour JF; Australasian Leukaemia and Lymphoma Group. Iland HJ, et al. Lancet Haematol. 2015 Sep;2(9):e357-66. doi: 10.1016/S2352-3026(15)00115-5. Epub 2015 Aug 20. Lancet Haematol. 2015. PMID: 26685769 Clinical Trial.
Patients with genetic variants of acute promyelocytic leukaemia (fusion of genes other than PML with RARA) were ineligible. ...INTERPRETATION: Incorporation of arsenic trioxide in initial therapy induction and consolidation for acute promyelocytic leukaemia reduced …
Patients with genetic variants of acute promyelocytic leukaemia (fusion of genes other than PML with RARA) were ineligible. ...INTERP …
Optimal scheduling to reduce morbidity of involved field radiotherapy with transplantation for lymphomas: a prospective Australasian Leukaemia and Lymphoma Group Study.
Wirth A, Prince HM, Wolf M, Stone JM, Matthews J, Gibson J, Macleod C, Szer J, Grigg A, To B, Roos D, Schwarer AP, Davis S; Australasian Leukaemia and Lymphoma Group. Wirth A, et al. Bone Marrow Transplant. 2005 Feb;35(3):291-8. doi: 10.1038/sj.bmt.1704759. Bone Marrow Transplant. 2005. PMID: 15558040 Clinical Trial.
Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia.
McQuilten ZK, Busija L, Seymour JF, Stanworth S, Wood EM, Kenealy M, Weinkove R; Australasian Leukaemia and Lymphoma Group (ALLG). McQuilten ZK, et al. Leuk Lymphoma. 2022 Mar;63(3):676-683. doi: 10.1080/10428194.2021.2012664. Epub 2021 Dec 17. Leuk Lymphoma. 2022. PMID: 34915809
We performed a post hoc analysis of two multicenter trials of azacitidine-based disease-modifying therapy for patients with MDS and low blast count acute myeloid leukemia (AML), to identify factors associated with QoL. 231 patients were included (median age 70 years). ...
We performed a post hoc analysis of two multicenter trials of azacitidine-based disease-modifying therapy for patients with MDS and low blas …
Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia.
Iland H, Bradstock K, Seymour J, Hertzberg M, Grigg A, Taylor K, Catalano J, Cannell P, Horvath N, Deveridge S, Browett P, Brighton T, Chong L, Springall F, Ayling J, Catalano A, Supple S, Collins M, Di Iulio J, Reynolds J; Australasian Leukaemia and Lymphoma Group. Iland H, et al. Haematologica. 2012 Feb;97(2):227-34. doi: 10.3324/haematol.2011.047506. Epub 2011 Oct 11. Haematologica. 2012. PMID: 21993673 Free PMC article. Clinical Trial.
BACKGROUND: Initial therapy for patients with acute promyelocytic leukemia most often involves the combination of all-trans-retinoic acid with anthracycline-based chemotherapy. ...DESIGN AND METHODS: In an attempt to minimize relapse and maximize survival for patients with …
BACKGROUND: Initial therapy for patients with acute promyelocytic leukemia most often involves the combination of all-trans-retinoic …
Prognostic features for response and survival in elderly patients with de novo acute myeloid leukemia treated with mitoxantrone and intermediate dose cytarabine.
Grigg AP, Reynolds J, McQuillan A, Juneja SK, Di Iulio J, Hui C, Smith C, Kimber R, Bradstock KF; Australasian Leukaemia and Lymphoma Group. Grigg AP, et al. Leuk Lymphoma. 2005 Mar;46(3):367-75. doi: 10.1080/10428190400013076. Leuk Lymphoma. 2005. PMID: 15621826 Clinical Trial.
Forty-three fit elderly patients with de novo acute myeloid leukemia (AML) received chemotherapy with mitoxantrone and intermediate dose cytarabine (MIDAC) in a phase II clinical trial conducted by the Australasian Leukaemia and Lymphoma Group. ...
Forty-three fit elderly patients with de novo acute myeloid leukemia (AML) received chemotherapy with mitoxantrone and intermediate d …
Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells.
Ross DM, Pagani IS, Shanmuganathan N, Kok CH, Seymour JF, Mills AK, Filshie RJ, Arthur CK, Dang P, Saunders VA, Braley J, Yong AS, Yeung DT, White DL, Grigg AP, Schwarer AP, Branford S, Hughes TP; Australasian Leukaemia and Lymphoma Group (ALLG). Ross DM, et al. Leukemia. 2018 Dec;32(12):2572-2579. doi: 10.1038/s41375-018-0264-0. Epub 2018 Oct 12. Leukemia. 2018. PMID: 30315232
Following the achievement of deep molecular response on tyrosine kinase inhibitors (TKIs), approximately half of patients with chronic myeloid leukemia (CML) can discontinue TKI and remain in treatment-free remission (TFR). ...Nine patients in long-term TFR were monitored …
Following the achievement of deep molecular response on tyrosine kinase inhibitors (TKIs), approximately half of patients with chronic myelo …
30 results